Current coffee consumption is associated with decreased striatal dopamine transporter availability in Parkinson’s disease patients and healthy controls

[1]  Xiaojun Xu,et al.  Association between cigarette smoking and Parkinson’s disease: a neuroimaging study , 2022, Therapeutic advances in neurological disorders.

[2]  N. Sousa,et al.  Habitual coffee drinkers display a distinct pattern of brain functional connectivity , 2021, Molecular Psychiatry.

[3]  D. Brooks,et al.  Clinical implications of early caudate dysfunction in Parkinson’s disease , 2019, Journal of Neurology, Neurosurgery, and Psychiatry.

[4]  E. Riboli,et al.  Exploring causality of the association between smoking and Parkinson’s disease , 2018, International journal of epidemiology.

[5]  J. DiNicolantonio,et al.  Coffee for Cardioprotection and Longevity. , 2018, Progress in cardiovascular diseases.

[6]  G. Defazio,et al.  Chronic coffee consumption and striatal DAT-SPECT findings in Parkinson’s disease , 2018, Neurological Sciences.

[7]  Hemant D. Tagare,et al.  Voxel-based logistic analysis of PPMI control and Parkinson's disease DaTscans , 2017, NeuroImage.

[8]  J. Schott,et al.  Clinical variables and biomarkers in prediction of cognitive impairment in patients with newly diagnosed Parkinson's disease: a cohort study , 2017, The Lancet Neurology.

[9]  A. Picco,et al.  Nigro-caudate dopaminergic deafferentation: a marker of REM sleep behavior disorder? , 2015, Neurobiology of Aging.

[10]  M. Zappia,et al.  Coffee consumption and risk of levodopa‐induced dyskinesia in Parkinson's disease: The FRAGAMP study , 2015, Movement disorders : official journal of the Movement Disorder Society.

[11]  S. Kühn,et al.  Feeling smart: Effects of caffeine and glucose on cognition, mood and self-judgment , 2015, Physiology & Behavior.

[12]  A. Petzer,et al.  Caffeine as a lead compound for the design of therapeutic agents for the treatment of Parkinson's disease. , 2015, Current medicinal chemistry.

[13]  Hui Qi,et al.  Dose–response meta‐analysis on coffee, tea and caffeine consumption with risk of Parkinson's disease , 2014, Geriatrics & gerontology international.

[14]  Dick J Veltman,et al.  Depressive symptoms in Parkinson's disease are related to reduced [123I]FP-CIT binding in the caudate nucleus , 2013, Journal of Neurology, Neurosurgery & Psychiatry.

[15]  M. Rodríguez-Violante,et al.  Caffeine drinking, cigarette smoking, and dopaminergic replacement therapy dose in Parkinson’s disease , 2013, Neurological Sciences.

[16]  M. McCullough,et al.  Caffeine and risk of Parkinson's disease in a large cohort of men and women , 2012, Movement disorders : official journal of the Movement Disorder Society.

[17]  D. German,et al.  Delayed caffeine treatment prevents nigral dopamine neuron loss in a progressive rat model of Parkinson's disease , 2012, Experimental Neurology.

[18]  M. Irizarry,et al.  Caffeine protects against combined paraquat and maneb-induced dopaminergic neuron degeneration , 2010, Experimental Neurology.

[19]  M. Schwarzschild,et al.  Neuroprotection by caffeine: time course and role of its metabolites in the MPTP model of Parkinson's disease , 2010, Neuroscience.

[20]  Ana M Sebastião,et al.  Caffeine and adenosine. , 2010, Journal of Alzheimer's disease : JAD.

[21]  Thomas Gasser,et al.  Neuropathological assessment of Parkinson's disease: refining the diagnostic criteria , 2009, The Lancet Neurology.

[22]  A. Reunanen,et al.  Prospective study of coffee consumption and risk of Parkinson's disease , 2008, European Journal of Clinical Nutrition.

[23]  Po See Chen,et al.  Decreased dopamine transporter availability in male smokers — A dual isotope SPECT study , 2008, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[24]  Caryn Lerman,et al.  Dopamine Transporter Binding in Smokers and Nonsmokers , 2007, Clinical nuclear medicine.

[25]  A. Köfalvi,et al.  Differential glutamate‐dependent and glutamate‐independent adenosine A1 receptor‐mediated modulation of dopamine release in different striatal compartments , 2007, Journal of neurochemistry.

[26]  A. Ascherio,et al.  Estrogen Prevents Neuroprotection by Caffeine in the Mouse 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine Model of Parkinson's Disease , 2006, The Journal of Neuroscience.

[27]  E. Oztaş,et al.  Neuroprotection by caffeine and more specific A2A receptor antagonists in animal models of Parkinson’s disease , 2003, Neurology.

[28]  George R Uhl,et al.  Dopamine transporter: Basic science and human variation of a key molecule for dopaminergic function, locomotion, and parkinsonism , 2003, Movement disorders : official journal of the Movement Disorder Society.

[29]  P. Aridon,et al.  A Case-Control Study on Cigarette, Alcohol, and Coffee Consumption Preceding Parkinson’s Disease , 2003, Neuroepidemiology.

[30]  T. Araki,et al.  Role of Dopamine Transporter Against MPTP (1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine) Neurotoxicity in Mice , 2003, Metabolic Brain Disease.

[31]  Andrew P. Smith,et al.  Effects of caffeine on human behavior. , 2002, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[32]  M. Schwarzschild,et al.  Neuroprotection by Caffeine and A2A Adenosine Receptor Inactivation in a Model of Parkinson's Disease , 2001, The Journal of Neuroscience.

[33]  E. Yoshikawa,et al.  Changes in dopamine availability in the nigrostriatal and mesocortical dopaminergic systems by gait in Parkinson's disease. , 2001, Brain : a journal of neurology.

[34]  C. Tanner,et al.  Association of coffee and caffeine intake with the risk of Parkinson disease. , 2000, JAMA.

[35]  B. Fredholm,et al.  Actions of caffeine in the brain with special reference to factors that contribute to its widespread use. , 1999, Pharmacological reviews.

[36]  M. Okada,et al.  Determination of the effects of caffeine and carbamazepine on striatal dopamine release by in vivo microdialysis. , 1997, European journal of pharmacology.

[37]  J. Mcculloch,et al.  Differential alterations in adenosine A1 and κ1 opioid receptors in the striatum in Alzheimer's disease , 1993, Brain Research.

[38]  M. Caron,et al.  Molecular characterization of the dopamine transporter. , 1993, Trends in pharmacological sciences.

[39]  S. Kish,et al.  Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications. , 1988, The New England journal of medicine.

[40]  Hal Blumenfeld,et al.  Semiquantitative Analysis of Dopamine Transporter Scans in Patients With Parkinson Disease , 2018, Clinical nuclear medicine.

[41]  J. Volkmann,et al.  Parkinson disease , 2017, Nature Reviews Disease Primers.

[42]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..

[43]  T. Dunwiddie,et al.  The Role and Regulation of Adenosine in the Central Nervous System , 2022 .